7H-吡咯并[2,3-h]喹唑啉-2-胺 | 827607-96-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 7H-吡咯并[2,3-h]喹唑啉-2-胺
• 英文名称: 7H-pyrrolo[2,3-h]quinazolin-2-amine
• CAS: 827607-96-5
• 化学式: C₁₀H₈N₄
• 分子量: 184.2
• InChiKey: WPRMHAIXFSDMKI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7H-吡咯并[2,3-h]喹唑啉-2-胺 在 吡啶 、 sodium hydride 作用下， 以 乙腈 为溶剂， 反应 19.83h， 生成 1-[2'-deoxy-β-D-ribofuranosyl]-5-[N-(dimethylamino)methylidene]aminopyrrolo[2,3-f]quinazoline
  参考文献：
  名称：

  yDNA：用于大小扩展碱基对的新几何。

  摘要：

  DOI：

  10.1002/anie.200461036
• 作为产物：
  描述：

  1-(苯磺酰基)-4-硝基吲哚-5-甲醛 在 palladium on activated charcoal 、 氢气 作用下， 以 甲醇 、 N,N-二甲基乙酰胺 为溶剂， 150.0 ℃ 、101.33 kPa 条件下， 生成 7H-吡咯并[2,3-h]喹唑啉-2-胺
  参考文献：
  名称：

  [EN] ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF
  [FR] CONJUGUÉS ANTICORPS-AGONISTES DE TLR, PROCÉDÉS ET UTILISATIONS DE CEUX-CI

  摘要：

  本文披露了TLR-激动剂化合物、抗体-TLR激动剂结合物、制药组合物以及使用这些化合物或结合物作为治疗癌症等疾病或病症的治疗剂的方法。

  公开号：

  WO2022040596A1

文献信息

• PROCESS FOR THE PREPARATION OF 2,4-DICHLORO-7H-PYRROLO[2,3H]QUINAZOLINE
  申请人：Kremer Kenneth Alfred Martin

  公开号：US20100036123A1

  公开（公告）日：2010-02-11

  The invention relates to a method of preparing 2,4-dichloro-7H-pyrrolo[2,3-h]quinazoline (II): from 1H-pyrrolo[2,3-h]quinazoline-2,4-dione.

  这项发明涉及一种从1H-吡咯并[2,3-h]喹唑啉-2,4-二酮制备2,4-二氯-7H-吡咯并[2,3-h]喹唑啉（II）的方法。
• [EN] ISOXAZOLO[5,4-H]QUINAZOLINE COMPOUNDS AS PROTEIN KINASE INHIBITORS<br/>[FR] COMPOSÉS ISOXAZOLO[5,4-H]QUINAZOLINE UTILISÉS EN TANT QU'INHIBITEURS DE PROTÉINE KINASE<br/>[ZH] 异噁唑并[5,4-H]喹唑啉类化合物作为蛋白激酶抑制剂
  申请人：CHENGDU SYNOWEST BIOTECHNOLOGY S R L

  公开号：WO2021043190A1

  公开（公告）日：2021-03-11

  通式(I)的异噁唑并[5,4-H]喹唑啉类化合物，它们可用于治疗细胞增殖障碍，是有效的细胞周期蛋白依赖性激酶(CDK)的抑制剂。
• WO2020168017A5
  申请人：——

  公开号：WO2020168017A5

  公开（公告）日：2023-02-22
• COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES
  申请人：Ambrx, Inc.

  公开号：US20220226488A1

  公开（公告）日：2022-07-21

  Disclosed herein are Trastuzumab-linked TLR-agonist derivative analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The Trastuzumab-linked TLR-agonist derivative analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid Trastuzumab-linked TLR-agonist derivative analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such Trastuzumab-linked TLR-agonist derivative analogs. Typically, the modified Trastuzumab-linked TLR-agonist derivative analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid Trastuzumab-linked TLR-agonist derivative analogs and modified non-natural amino acid Trastuzumab-linked TLR-agonist derivative analogs, including therapeutic, diagnostic, and other biotechnology use.
• [EN] OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF<br/>[FR] COMPOSITIONS D'OLIGONUCLÉOTIDES ET PROCÉDÉS ASSOCIÉS
  申请人：WAVE LIFE SCIENCES LTD

  公开号：WO2017062862A2

  公开（公告）日：2017-04-13

  Among other things, the present disclosure relates to designed oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide altered splicing of a transcript. In some embodiments, provided oligonucleotide compositions have low toxicity. In some embodiments, provided oligonucleotide compositions provide improved protein binding profiles. In some embodiments, provided oligonucleotide compositions have improved delivery. In some embodiments, provided oligonucleotide compositions have improved uptake. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions.